RBC keeps CHF 400 target as Roche Holding stock nears results

Published on 10/21/2026 at 10:26 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Roche will publish third-quarter sales on October 22, 2026. Roche Holding stock costs EUR 421.28 on October 21, 2026, with CHF 310.8 billion market value.

Roche timeline and valuation

RBC maintained an Outperform rating and a CHF 400.00 target on October 19, 2026.
Roche will publish third-quarter 2026 sales on October 22, 2026.
Roche Holding stock traded at EUR 421.28 at 10:17 a.m. CEST at Lang & Schwarz on October 21, 2026.

Automatisches Diagnostik-Laborgerät mit Touchscreen-Oberfläche im klinischen Labor — Roche Holding AG CH0012032048 – Diagnostik-Analysegerät verarbeitet biologische Proben im modernen klinischen Labor, Illustration mit AI erstellt.

Roche Holding (ISIN CH1499059983) was trading at EUR 421.28 at Lang & Schwarz on October 21, 2026, at 10:17 a.m. CEST. The company is approaching its third-quarter sales update, while RBC has kept an Outperform rating and a CHF 400.00 price target.

RBC keeps target at CHF 400

According to MarketScreener on October 19, 2026, RBC retained its Outperform view and CHF 400.00 target. Analyst Trung Huynh said RBC's third-quarter revenue forecast was 2.70 percent above consensus.

The same report carried a clear counter-factor: Roche could face pressure if results merely meet expectations because the shares were trading near record levels. That makes the October sales release the next test for the bullish research view.

What comes next for sales?

Roche will publish third-quarter 2026 sales before the Swiss Stock Exchange opens on October 22, 2026, according to Roche. The company scheduled its investor presentation for 2:00 p.m. CEST the same day.

Roche's investor page lists CHF 19.46 in diluted core earnings per share for fiscal year 2025, with core earnings per share growth of 11.00 percent at constant exchange rates. It also states that 39 million patients received Roche medicines in fiscal year 2025, giving the upcoming sales release a broad operating context.

The next listed investor event is the Berenberg Pharma CFO Series on November 2, 2026, according to Roche's investor calendar. Roche operates across pharmaceuticals and diagnostics, so the sales update can show whether both divisions are supporting the revenue outlook.

Stock trades in euros

Roche Holding had a market capitalization of CHF 310.8 billion as of October 20, 2026. The current euro quotation therefore sits alongside a large Swiss franc valuation base, while the next company-specific catalyst is dated October 22, 2026.

Roche Holding stock was trading at EUR 421.28 at Lang & Schwarz on October 21, 2026, at 10:17 a.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of Roche Holding stock.